TG Therapeutics (TGTX) revenue breakdown
By product, Product is the largest at 98% of fiscal 2025 revenue, growing 210% a year over 4 years.
Revenue by product
Fiscal years, as TG Therapeutics reports them in its 10-K filings; fiscal 2025 total $616M.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Product | $7M | $3M | $92M | $314M | $607M | 98% |
| Royalty | — | — | — | $801,000 | $6M | 1% |
| Other Revenue | — | — | $2M | $2M | $4M | 1% |
| License Revenue | $152,000 | $152,000 | $140M | $152,000 | $152,000 | 0% |
| Milestone | — | — | — | $12M | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TGTX.
Open TGTX in InvestinglyQuestions
Where does TG Therapeutics make its money?
In fiscal 2025, by product: Product $607M, Royalty $6M, Other Revenue $4M, License Revenue $152,000.
From TG Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.